Agenus

Agenus AGEN Stock

$6.35   2.254390%
Add to favorites
Market Cap
$287.32M
LOW - HIGH [24H]
$5.98 - $6.50
VOLUME [24H]
$686.21K
P/E Ratio
27.60
Earnings per share
$0.23
ISIN
US00847G8042
Price   Prediction

Agenus Price Chart

Sorry, that's all we've gotfor now...

Agenus (AGEN) stock price today is 6.35 USD on Tech Market Small (+2.25% on the day). Updated .

Agenus AGEN Financial and Trading Overview

Agenus stock price 6.35 USD
Previous Close 6.21 USD
Open 6.17 USD
Bid 4.5 USD x 200
Ask 7.93 USD x 200
Day's Range 5.98 - 6.46 USD
52 Week Range 2.71 - 10.31 USD
Volume 368.37K USD
Avg. Volume 951.67K USD
Market Cap 287.99M USD
Beta (5Y Monthly) 1.523
PE Ratio (TTM) 27.673912
EPS (TTM) 0.23 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 27 USD

AGEN Valuation Measures

Enterprise Value 226.72M USD
Trailing P/E 27.673912
Forward P/E -39.78125
PEG Ratio (5 yr expected) 1.44
Price/Sales (ttm) 2.1500757
Price/Book (mrq) N/A
Enterprise Value/Revenue 1.693
Enterprise Value/EBITDA 4.171

Trading Information

Agenus Stock Price History

Beta (5Y Monthly) 1.523
52-Week Change 47.85%
S&P500 52-Week Change 10.51%
52 Week High 10.31 USD
52 Week Low 2.71 USD
50-Day Moving Average 7.3 USD
200-Day Moving Average 5.14 USD

AGEN Share Statistics

Avg. Volume (3 month) 951.67K USD
Avg. Daily Volume (10-Days) 728.99K USD
Shares Outstanding 45.25M
Float 38.03M
Short Ratio 8.23
% Held by Insiders 6.23%
% Held by Institutions 58.32%
Shares Short 7.6M
Short % of Float 17.00%
Short % of Shares Outstanding 16.80%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:20

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 30.77%
Operating Margin (ttm) 38.93%
Gross Margin 122.88%
EBITDA Margin 40.58%

Management Effectiveness

Return on Assets (ttm) 13.59%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 133.95M USD
Revenue Per Share (ttm) 3.03 USD
Quarterly Revenue Growth (yoy) 4.10%
Gross Profit (ttm) 164.6M USD
EBITDA 54.36M USD
Net Income Avi to Common (ttm) 30.61M USD
Diluted EPS (ttm) 0.23
Quarterly Earnings Growth (yoy) -93.89%

Balance Sheet

Total Cash (mrq) 86.94M USD
Total Cash Per Share (mrq) 1.92 USD
Total Debt (mrq) 39.46M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.728
Book Value Per Share (mrq) -2.331

Cash Flow Statement

Operating Cash Flow (ttm) -103862000 USD
Levered Free Cash Flow (ttm) -920000 USD

Profile of Agenus

Country United States
State MA
City Lexington
Address 3 Forbes Road
ZIP 02421-7305
Phone 781 674 4400
Website https://www.agenusbio.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 81

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Q&A For Agenus Stock

What is a current AGEN stock price?

Agenus AGEN stock price today per share is 6.35 USD.

How to purchase Agenus stock?

You can buy AGEN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Agenus?

The stock symbol or ticker of Agenus is AGEN.

Which industry does the Agenus company belong to?

The Agenus industry is Biotechnology.

How many shares does Agenus have in circulation?

The max supply of Agenus shares is 45.25M.

What is Agenus Price to Earnings Ratio (PE Ratio)?

Agenus PE Ratio is 27.60869400 now.

What was Agenus earnings per share over the trailing 12 months (TTM)?

Agenus EPS is 0.23 USD over the trailing 12 months.

Which sector does the Agenus company belong to?

The Agenus sector is Healthcare.

Agenus AGEN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24450.37 USD —
+0.5
5.97B USD — 24225.3 USD — 24538.78 USD — — 5.97B USD —
us US Tech Health Care IXHC US 1324.83 USD —
-0.6
— — 1322.85 USD — 1342.46 USD — — — —
us US Tech Composite Total Return XCMP US 30202.3 USD —
+0.46
— — 29937.56 USD — 30324.94 USD — — — —
us US Tech Capital Market Composite RCMP US 108.83 USD —
+0.13
— — 108.35 USD — 109.95 USD — — — —
$2.16T
Total marketcap
$71.41B
Total volume
BTC 58.01%   •   ETH 9.87%
Dominance
Select currency